Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v37.i2-6.110
pages 445-461

Cellular Mucins: Targets for Immunotherapy

Vasso Apostolopoulos
The Austin Research Institiute, Studley Road, Heidelberg 3084, Victoria, Australia
Ian F. C. McKenzie
The Austin Research Institiute, Studley Road, Heidelberg 3084, Victoria, Australia

RESUMO

Mucins are attracting great interest as potential targets for immunotherapy in the development of vaccines for cancers expressing Mucinl (MUC1) (e.g., breast, pancreas, ovary, and others) as there is (1) a 10-fold increase in the amount in adenocarcinomas; (2) an alteration in expression where they become ubiquitous, and (3) due to altered glycosylation, new epitopes appear on the cell surface that are absent in normal tissues. These new epitopes can be carbohydrate; others are peptide in nature. The cloning of the cDNAs from mucins, particularly MUC1, has led to rapid advances being made, and it is clear that a highly immunogenic peptide exists within the variable number of tandem repeats (VNTR) found in all mucins. This peptide is immunogenic in mice, giving rise to strong antibody production, and most monoclonal antibodies made to breast cancer, which react with the protein core, react with the peptide APDTR. It is now also clear that humans with breast cancer have, in their draining lymph nodes, precursors of cytotoxic T cells that can be stimulated in vitro to react against breast cancer and indeed against the APDTR or a closely related peptide − shown from antibody-blocking studies. These CTLs are unique in that they are non-MHC restricted. The identification of suitable targets, coupled with the known immunogenicity of both the peptide and neo-carbohydrate epitopes, has led to the development of several different programs to immunize humans against breast cancer using either synthetic carbohydrates or peptides conjugated with adjuvants, and clinical trials are now in progress to evaluate their immunogenicity and anti-cancer effects.


Articles with similar content:

Cellular Mucins: Targets for Immunotherapy
Critical Reviews™ in Immunology, Vol.14, 1994, issue 3-4
Vasso Apostolopoulos , Ian F. C. McKenzie
Improving the Management of Bladder Cancer with Fluorescence Cystoscopy
Journal of Environmental Pathology, Toxicology and Oncology, Vol.26, 2007, issue 2
H. Barton Grossman
Targeted Breast Cancer Nanotherapeutics: Options and Opportunities with Estrogen Receptors
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 5
Rishi Paliwal, Govind P Agrawal, Shivani Rai Paliwal, Suresh P. Vyas
Genomic Pathology and Cancer Biomarkers: Prostate Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Kenneth A. Iczkowski
Tumor Cell Recognition by Lymphocytes: Is the MHC Always Essential?
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Beverly Z. Packard , Akira Komoriya